Insmed CFO Sara Bonstein to step down, reaffirms guidance
Insmed announced that CFO Sara Bonstein will step down on October 30th after nearly seven years with the company. She will remain CFO through Q3 financial reporting, and a search for her successor is underway. Insmed also reaffirmed its 2026 revenue guidance for BRINSUPRI and ARIKAYCE.
Insmed Q2 2026 Earnings Call Transcript
Insmed reported strong financial results for Q2 2026, with Brensocatib revenue reaching $309.2 million, a 49% increase from the prior quarter. The company raised its full-year 2026 Brensocatib revenue guidance to $1.25 to $1.4 billion and increased peak sales estimates for Brensocatib and TPIP to over $7 billion and $6 billion, respectively. Insmed is also advancing its pipeline and expects to achieve cash flow positivity by 2027 without needing additional capital.
Insmed Incorporated Reaffirms Earnings Guidance for the Full-Year 2026
Insmed Incorporated has reaffirmed its financial guidance for the full-year 2026, projecting revenue for BRINSUPRI® (brensocatib) to be between $1.25 billion and $1.40 billion. Additionally, the company expects ARIKAYCE® (amikacin liposome inhalation suspension) to generate revenues ranging from $450 million to $470 million. This reaffirmation highlights Insmed's focus on operational excellence and continued momentum.
Insmed CFO Sara Bonstein to Separate, Search Underway for Successor
Insmed announced that its Chief Financial Officer, Sara Bonstein, will be separating from the company effective October 30, 2026. A search is currently underway to find her successor. The company stated that her departure is not due to any disagreements regarding accounting, financial statements, internal controls, or operations.
Insmed CFO Sara Bonstein to step down on October 30 By Investing.com
Insmed Incorporated announced that CFO Sara Bonstein will step down on October 30, 2026, after nearly seven years with the company. Bonstein will remain through the Q3 2026 financial results reporting and earnings call. Insmed has initiated a search for her successor and reaffirmed its full-year 2026 financial guidance for BRINSUPRI and ARIKAYCE revenues.
Insmed Announces CFO Transition
Insmed Incorporated announced that CFO Sara Bonstein will step down on October 30, 2026, after nearly seven years with the company. She will remain until then to ensure a smooth transition and participate in the third-quarter 2026 earnings call on October 29. The company reaffirmed its full-year 2026 financial guidance for BRINSUPRI and ARIKAYCE revenues and has initiated a search for a new CFO.
After nearly seven years, Insmed’s CFO will step down Oct. 30.
Insmed announced that CFO Sara Bonstein will step down on October 30, 2026, after nearly seven years with the company, to pursue a broader leadership role. She will remain in her position through the third-quarter financial reporting and participate in the October 29 earnings call. Insmed reaffirmed its full-year 2026 revenue guidance for BRINSUPRI ($1.25 billion to $1.40 billion) and ARIKAYCE ($450 million to $470 million) and expects to achieve cash flow positivity next year.
How Investors Are Reacting To Insmed (INSM) Priority Review Acceptance
Insmed (INSM) received Priority Review for its sNDA for ARIKAYCE for MAC lung disease, supported by positive Phase 3b ENCORE data, with a PDUFA target action date of January 28, 2027. This development could broaden ARIKAYCE's use earlier in the disease course and diversify Insmed's revenue mix alongside its brensocatib launch. The company's narrative projects significant revenue and earnings growth by 2029, though some analysts maintain a more cautious outlook on label expansion.
INSM5182680 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the INSM5182680 bond issued by Insmed Incorporated. It covers key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes information on the bond's 0.75% semi-annual fixed-rate coupon payments and an upcoming payout schedule.
Insmed Incorporated - Common Stock (Nasdaq:INSM) Stock Quote
This page provides a detailed stock quote for Insmed Incorporated (INSM) on Nasdaq, showing its current price, daily range, 52-week range, and trading volume. It also includes performance metrics, recent news headlines related to the company, and answers to frequently asked questions about INSM's public trading status and market capitalization. The stock last traded at $111.12, 47.8% below its 52-week high, with a 12-month return of -29.3%.
Why (INSM) Price Action Is Critical for Tactical Trading
This article analyzes Insmed Incorporated (INSM) stock, highlighting weak sentiment across all time horizons and suggesting a short bias. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal analysis. The analysis emphasizes an exceptional risk-reward setup targeting a significant gain with minimal risk.
Insmed | 10/1/26
TV host and designer Ty Pennington is raising awareness about bronchiectasis (BE), a chronic lung disease, during Healthy Lung Month. He shares his family's personal experience with the condition to encourage others with persistent respiratory symptoms to seek diagnosis and speak with their healthcare providers. This awareness campaign, "Suspect BE," is sponsored by Insmed.
3 AI Healthcare Stocks With At Least 8% Revenue Growth
This article highlights three AI-driven healthcare stocks—Insmed (INSM), Hinge Health (HNGE), and Stryker (SYK)—that demonstrate at least 8% revenue growth. It discusses how these companies are leveraging AI to innovate in areas like protein engineering, digital musculoskeletal care, and hospital technology. The piece emphasizes the importance of AI applications that address significant problems, especially as investment capital becomes more discerning.
Insmed Price Target Cut to $207.00/Share From $237.00 by Barclays
Barclays has lowered its price target for Insmed to $207.00 per share, down from the previous target of $237.00. Despite the reduction in the price target, the firm has maintained an "Overweight" rating on the company's stock. This adjustment reflects Barclays' updated outlook on Insmed's valuation.
Net income before discontinued operations of Insmed Incorporated – HAN:IM8N
This article presents financial data for Insmed Incorporated (IM8N) listed on the Hannover Stock Exchange, specifically focusing on its net income before discontinued operations. The content appears to be a stub or a section from a larger financial overview on TradingView, indicating that more detailed figures would typically be displayed here. The page structure also includes various links to other financial tools and community features.
Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
Insmed announced strong financial results for the second quarter of 2022, with ARIKAYCE revenue growing 44% year-over-year to $65.2 million, marking its strongest quarter since launch. The company reiterated its guidance for at least 30% revenue growth in 2022 and stated that its cash reserves will support ongoing programs into 2024. Insmed also provided updates on its clinical programs for brensocatib and TPIP, which are progressing on track, and outlined plans for new indications and translational medicine efforts.
Total liabilities & shareholders' equities of Insmed Incorporated – HAN:IM8N
This page provides financial data on Insmed Incorporated (HAN:IM8N), specifically focusing on its total liabilities and shareholders' equities. The information is presented by TradingView and includes data from various financial service providers like ICE Data Services and FactSet.
Insmed 15-year return: $1,000 investment grows to $27,361
Insmed (NASDAQ: INSM) has delivered an average annual return of 24.7% over the past 15 years, significantly outperforming the broader market. A $1,000 investment made 15 years ago would now be worth $27,361.95, highlighting the power of long-term holding in high-growth equities. The company currently has a market capitalization of $25.54 billion.
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
The healthcare sector is demonstrating strong momentum in 2026, driven by GLP-1 medications, AI applications in drug discovery, and potential M&A activity. This article highlights three healthcare companies—Oscar Health, Hinge Health, and Insmed—each showing promise through improving profitability, revenue growth, or the launch of innovative treatments. Despite sector risks, these firms exhibit significant growth potential and strong analyst ratings.
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ: INSM) has significantly outperformed the market over the last 15 years, achieving an average annual return of 24.7%. An investment of $1000 in INSM stock 15 years ago would now be valued at $27,361.95. This demonstrates the powerful effect of compounded returns on investment growth over time.
Insmed (INSM) Could Be 40% Undervalued On FDA Priority Review News
Insmed (INSM) has received FDA Priority Review for its supplemental New Drug Application for ARIKAYCE, leading to speculation that the stock is 40% undervalued despite recent short-term share price drops. The company's fair value is estimated at $197.14 against a current close of $117.83, driven by a strong pipeline and upcoming catalysts like the U.S. launch of brensocatib. However, the article also notes a high P/S ratio, suggesting investors are already paying a premium based on future earnings potential.
Goldman Sachs Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $188
Goldman Sachs has reiterated its Buy rating on Insmed (INSM.US) but has reduced the target price for the stock to $188. This adjustment indicates continued confidence in the company's prospects despite a lower price target.
Learn Why The Bull Case For Insmed Stock Could Change Following Priority Review Acceptance
Insmed recently received Priority Review acceptance from the FDA for its ARIKAYCE supplemental New Drug Application for MAC lung disease, backed by strong Phase 3b ENCORE data. This development positions ARIKAYCE as a potential earlier line treatment and strengthens Insmed's rare disease portfolio. While ARIKAYCE's progress diversifies revenue, the company's near-term upside still heavily relies on the timely FDA review and commercial success of brensocatib for bronchiectasis.
Insmed Incorporated (INSM) stock price, news, quote and history
Insmed Incorporated (INSM) is a biotechnology company focused on developing therapies for serious and rare diseases. The company's stock closed at $118.34, down 2.05%, with a market cap of $25.843 billion. Insmed has several drugs in various clinical trial phases for conditions like nontuberculous mycobacterial lung infections, bronchiectasis, and pulmonary hypertension, and also engages in preclinical research in gene therapy and AI-driven protein engineering.
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
The FDA has accepted Insmed's regulatory filing for a label expansion of Arikayce to include newly diagnosed mycobacterium avium complex (MAC) lung disease patients, granting it priority review with a decision expected by January 28, 2027. This expansion, supported by positive Phase IIIb ENCORE study results, could significantly enlarge Arikayce's addressable market beyond the current refractory MAC lung disease population. Insmed anticipates engaging with Japanese regulatory authorities for a similar expansion in late 2026.
Insmed stock price target maintained at $195 by Mizuho on FDA review
Mizuho has reiterated an Outperform rating and a $195 price target for Insmed (NASDAQ: INSM) following the FDA's acceptance of the company's supplemental new drug application for Arikayce as a first-line treatment for Mycobacterium avium complex lung disease. The FDA granted priority review with a PDUFA date of January 28, 2027, which is expected to significantly expand Arikayce's market opportunity. This news, combined with strong revenue growth and positive trends for their other drug, Brinsupri, reinforces Insmed's market momentum.
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Insmed announced that the FDA has accepted its regulatory filing for label expansion of Arikayce in mycobacterium avium complex (MAC) lung disease, granting it priority review with a decision expected by January 28, 2027. This expansion aims to approve Arikayce for newly diagnosed MAC lung disease patients and significantly increase its addressable market beyond the current refractory MAC population. The filing is supported by positive results from the phase IIIb ENCORE study, which met its primary and key secondary endpoints.
Insmed’s Arikayce label expansion filing gets January 2027 PDUFA date
The US FDA has granted Priority Review to Insmed's supplemental New Drug Application (sNDA) for Arikayce, an inhaled antibiotic, aiming for full approval for Mycobacterium avium complex (MAC) lung disease as part of a combination regimen. The PDUFA target action date is January 28, 2027. This filing seeks to convert Arikayce's existing accelerated approval to include newly diagnosed patients, supported by positive results from the Phase IIIb ENCORE study, which showed earlier, greater, and more durable culture conversion with no new safety signals.
FDA grants Priority Review to Insmed's ARIKAYCE for full approval in treating MAC lung disease
The FDA has granted Priority Review to Insmed's Supplemental New Drug Application for ARIKAYCE, an inhaled antibiotic used to treat Mycobacterium avium complex (MAC) lung disease, setting a target decision date of January 28, 2027. This application for full approval is supported by positive Phase 3b ENCORE study results, which showed significant improvements in respiratory symptoms and culture conversion. Full approval could enable earlier use of ARIKAYCE in the disease progression, potentially benefiting more patients, and Insmed also plans to pursue label expansion in Japan.
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
The FDA has granted Priority Review to Insmed's Supplemental New Drug Application (sNDA) for ARIKAYCE (amikacin liposome inhalation suspension) for treating Mycobacterium avium complex (MAC) lung disease, with a target action date of January 28, 2027. This sNDA seeks full approval, enabling earlier treatment for patients, and is supported by positive results from the Phase 3b ENCORE study, which met its primary and secondary endpoints. ARIKAYCE previously received accelerated approval for refractory MAC lung disease and is now aiming for broader availability.
Discipline and Rules-Based Execution in INSM Response
Insmed Incorporated (NASDAQ: INSM) is showing near-term weak sentiment that may lead to a resumption of long-term weakness. An exceptional 64.4:1 risk-reward short setup is identified, targeting an 18.8% downside with minimal risk. AI models have generated three distinct trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies.
Insmed Incorporated (INSM) Gets FDA Priority Review; PDUFA Jan 28, 2027
Insmed (INSM) announced that the FDA has granted Priority Review to its sNDA for ARIKAYCE, intended for MAC lung disease. The Prescription Drug User Fee Act (PDUFA) target action date for a decision is set for January 28, 2027. This regulatory milestone could significantly impact the company's revenue and valuation if the FDA decision is favorable.
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed Incorporated announced that the FDA has granted Priority Review to its Supplemental New Drug Application (sNDA) for ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease. The PDUFA target action date is January 28, 2027. This application, based on positive Phase 3b ENCORE study results, aims for full approval which would allow ARIKAYCE to be used earlier in the disease course and fulfills a post-marketing requirement from the FDA.
Insmed receives FDA priority review for ARIKAYCE
Insmed (NASDAQ:INSM) has received FDA Priority Review for a supplemental application seeking full approval of ARIKAYCE for Mycobacterium avium complex (MAC) lung disease, with a PDUFA target action date of January 28, 2027. This application aims to expand ARIKAYCE's use earlier in the disease course, supported by positive data from the Phase 3b ENCORE trial. ARIKAYCE previously received accelerated approval in 2018, and this filing addresses a post-marketing requirement, with Insmed also planning discussions with Japan's PMDA for label expansion.
Insmed Incorporated (INSM) Stock Report: A Biotech Powerhouse with 66% Potential Upside
Insmed Incorporated (INSM) is presented as a compelling investment opportunity in the biotechnology sector, despite current unprofitability, due to its robust pipeline and strong analyst confidence. With a market cap of $26.21 billion, the company focuses on therapies for rare diseases, and analysts project a potential upside of 66.29%, setting an average target price of $199.55. Its flagship product, ARIKAYCE, and other clinical-stage developments highlight its innovative approach and potential for future growth.
INSMED Inc Director Brennan David R Sells 25,000 Shares at $124 Each on September 9, 2026
INSMED Inc Director Brennan David R sold 25,000 shares of the company's stock at $124 per share on September 9, 2026. This transaction reduced his holdings by approximately 38.9%, leaving him with 39,238 shares. The sale provides insight into the director's current ownership stake in INSMED.
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Insmed Incorporated announced that it will present five abstracts from its respiratory portfolio at the European Respiratory Society (ERS) Congress 2026 in Barcelona, from September 5-9, 2026. Key presentations include late-breaking results from the Phase 3b ENCORE study for ARIKAYCE in newly diagnosed Mycobacterium avium complex lung infection, as well as post hoc analyses for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) and BRINSUPRI in non-cystic fibrosis bronchiectasis (NCFB). The company also plans to present data on the psychosocial burden and healthcare resource utilization associated with bronchiectasis.
Insmed Grants Inducement Awards to 128 New Employees
Insmed has granted inducement awards to 128 new employees under its 2025 Inducement Plan to attract talent and comply with Nasdaq listing requirements. These new employees received a total of 115,320 restricted stock units and options to purchase 5,560 shares, which will vest over four years. This initiative aims to enhance the company's talent acquisition, market competitiveness, and foster employee loyalty.
Insmed (INSM) Q1 2025 Earnings: Results, Market Reaction & History
Insmed (INSM) reported mixed Q1 2025 earnings, beating revenue expectations with $92.82 million, driven by strong ARIKAYCE sales, but missing EPS estimates with a loss of $1.42 due to increased pre-launch spending for brensocatib. The company reaffirmed its full-year 2025 ARIKAYCE revenue guidance and anticipates significant catalysts, including brensocatib's FDA PDUFA date in August 2025. This strategic investment aims to capitalize on future growth from its pipeline assets.
Insmed director Sharoky sells $637,650 of Insmed stock
Insmed director Melvin Sharoky sold 5,000 shares of INSMED Inc. (NASDAQ:INSM) common stock on August 17, 2026, for a total of $637,650. Despite this insider sale, analysts maintain a "strong buy" consensus for INSMED, with price targets indicating significant upside potential. The company recently reported strong Q2 revenue and raised its full-year sales outlook, driven by its lung-disease drugs BRINSUPRI and ARIKAYCE.
Brinsupri/Brensocatib Approved for Bronchiectasis in Japan
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib 25-mg tablet) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 and older. This marks the first MHLW-approved treatment for NCFB, offering a new option for managing this chronic disease. The approval is based on results from the Phase 3 ASPEN study, which showed brensocatib significantly reduced pulmonary exacerbations and slowed lung function decline.
Insmed to Present at September 2026 Investor Conferences
Insmed Incorporated announced that its management will present at two investor conferences in September 2026: the 12th Annual Cantor Fitzgerald Global Healthcare Conference and the 24th Annual Morgan Stanley Global Healthcare Conference. Both events will be webcast live on the company's investor relations website. Insmed is a global biopharmaceutical company focused on developing therapies for serious diseases, with a diverse portfolio and a strong research engine.
Insmed director Melvin Sharoky sells $637,650 in shares
Insmed director Melvin Sharoky indirectly sold 5,000 shares of the company's common stock for $637,650 on August 17, 2026, through Padonia, LLC. Despite the sale occurring near recent highs, Wall Street analysts maintain optimistic price targets for INSMED, which has seen significant revenue growth and strong performance from its lung-disease drugs. The company recently raised its full-year revenue guidance for BRINSUPRI and received regulatory approval in Japan for the drug.
Mizuho raises Insmed stock price target to $195 on Japan approval
Mizuho increased its price target for Insmed shares to $195 from $192, maintaining an Outperform rating after Japan approved Brinsupri for non-cystic fibrosis bronchiectasis. This approval led Mizuho to raise its probability-of-success assumption for Brinsupri in Japan to 100%. The firm believes the recent share weakness is unwarranted given strong company fundamentals and Brinsupri's launch success, also highlighted by a recent significant revenue beat for the drug.
Insmed receives Japan approval for BRINSUPRI bronchiectasis treatment
Insmed has received approval from Japan’s Ministry of Health, Labour and Welfare for BRINSUPRI (brensocatib) to treat non-cystic fibrosis bronchiectasis. This approval makes BRINSUPRI the first and only treatment for the condition in Japan, following its authorization in the United States and Europe. The approval is based on results from the Phase 3 ASPEN study, which showed that brensocatib reduced pulmonary exacerbations and was generally well tolerated.
Japan approves the first treatment for a chronic lung disease that can damage lungs
Insmed (Nasdaq: INSM) has announced that Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25 mg) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 and older. This makes BRINSUPRI the first and only approved treatment for NCFB in Japan, adding to its existing authorizations in the U.S. and Europe. The approval is based on positive results from the Phase 3 ASPEN study, which showed a significant reduction in pulmonary exacerbations and improved lung function compared to placebo.
Insmed Incorporated (INSM): Analyst Consensus Projects 59% Upside—A Biotech Powerhouse with Robust Growth Potential
Insmed Incorporated (INSM) is an intriguing biotech stock with a current market cap of $27.47 billion, focusing on therapies for rare diseases. Analysts project a 59.06% upside with a target price of $200.05 and 23 unanimous buy ratings. Despite significant revenue growth of 296.10%, the company faces profitability challenges with negative net income, ROE, and free cash flow due to heavy R&D investments, yet it boasts a robust product pipeline and bullish technical indicators.
Biotech Is Booming, But These 2 Stocks Missed the Memo
While the biotech sector is experiencing a significant boom, with the iShares Biotechnology ETF reaching new highs and many top stocks surging, Alnylam Pharmaceuticals and Insmed Inc. have significantly underperformed. Alnylam's stock dropped due to a cut in its revenue guidance for 2026, stemming from an initial inflated demand for its Amvuttra drug, while Insmed's underperformance is notable amidst widespread sector growth. Both companies' recoveries may depend on specific internal catalysts rather than broader market tailwinds.
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares
Insmed's stock dropped 4.3% due to a combination of post-earnings profit-taking and significant insider stock sales. The company had previously seen a rally after reporting strong Q2 2026 results and increased guidance for its key products. Recent regulatory filings showed several executives, including the COO and CMO, sold substantial amounts of shares after exercising options.
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC
Insmed (NASDAQ: INSM) director Melvin Sharoky, MD, indirectly sold 5,000 shares of common stock through Padonia, LLC on August 17, 2026, at a weighted average price of $127.53 per share. Following this transaction, Padonia, LLC holds zero shares, while Dr. Sharoky retains 246,081 shares directly and additional shares indirectly through his spouse and custodial accounts. The sale was not marked as being under a Rule 10b5-1 trading plan.
